Korea’s top biopharmaceutical firms, Celltrion and Samsung Biologics, envisioned their future strategies for expansion at J.P ...

SK Biopharmaceuticals and Eurofarma formed a joint venture to develop an AI platform for managing epilepsy. The focus ...

SK Biopharmaceuticals Co. (SK Biopharm), a biopharmaceutical arm of SK Group, will establish a joint venture with a major ...

SK Biopharmaceuticals plans to establish a joint venture with Eurofarma, one of Latin America’s leading pharmaceutical ...

Common measurements for modified adeno-associated viruses (AAVs), a gene therapy delivery method, showed substantial ...

In Canada, 1 in 12 people live with a rare disease, and for most people suffering from these diseases, the cost of treatment is unaffordable. Canadians deserve a health care system that provides ...

CO. Ltd, today announced the first patient dosing in Australia on Dec 30, 2024 for Phase 1 clinical trial of HX044 in patients with advanced solid tumors.

Ltd, today announced the first patient dosing in Australia on Dec 30, 2024 for Phase 1 clinical trial of HX044 in patients with advanced solid tumors.

Overview: UPM-Kymmene Oyj, along with its subsidiaries, operates in the forest-based bioindustry across Europe, North America, Asia, and internationally with a market cap of €14.17 billion. Operations ...

We've identified the following companies as similar to Sk Biopharmaceuticals Co Ltd because they operate in a related industry or sector. We also considered size, growth, and various financial metrics ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...